Prestige Biologics CEO Kim Michael Jin-woo Buys 100,000 Shares Showcasing Insider Confidence Amid Share Dilution from Prior Issuance

Prestige Biologics CEO and major shareholder Kim Michael Jin-woo purchased an additional 100,000 common shares through open market purchases from June 24 to June 30, 2026.
Purchase prices ranged from 1,814 KRW to 1,946 KRW, with total consideration of approximately 180 million KRW.
Kim's holdings increased to 7,811,601 shares, but his ownership percentage dropped from 16.30% to 10.05% due to an increase in total outstanding shares from 47,320,139 to 77,752,637.
The current stock price is 1,945 KRW with a market capitalization of approximately 151.2 billion KRW. Insider buying is generally viewed as a signal of management confidence.
[AI Summary]While the CEO's open market purchase is a positive insider signal, the acquisition size is negligible relative to total shares outstanding and thus has limited direct price impact. The decline in ownership percentage implies dilution for existing shareholders, warranting investor attention to the reasons behind the increase in outstanding shares.